059-20 Wyo. Code R. §§ 20-5 - Collaborative Pharmacist Care
(a) A pharmacist planning to engage in
collaborative practice shall have on file at the pharmacist's place of practice
a written, signed collaborative practice agreement approved by the Board. This
collaborative practice agreement allows the pharmacist, acting within the
pharmacist's collaborative scope of practice, to conduct MTM approved by a
prescribing practitioner acting within the scope of the practitioner's current
practice.
(b) The collaborative
practice agreement shall include:
(i) The
names of the prescribing practitioner and the pharmacist who are parties to the
collaborative practice agreement;
(ii) The specific types of MTM decisions that
the pharmacist is allowed to make, which shall include:
(A) The types of diseases, drugs or drug
categories involved, and the extent of MTM allowed in each case;
(B) The methods, procedures, decision
criteria and plan the pharmacist is to follow when conducting MTM;
and
(C) The procedures the
pharmacist is to follow in the course of conducting MTM, including
documentation of decisions and a plan or appropriate mechanism for
communication and reporting to the prescribing practitioner concerning specific
decisions. Documentation of decisions shall occur in the prescribing
practitioner patient medical record. If the medical record is not available at
the practice site, a copy of the documentation of decisions will be sent to the
prescribing practitioner.
(iii) A method for the prescribing
practitioner to monitor compliance with the collaborative practice agreement
and clinical outcomes when MTM by the pharmacist has occurred and to intercede
when necessary;
(iv) A provision
that allows the prescribing practitioner to override the collaborative practice
agreement whenever deemed necessary or appropriate;
(v) A provision allowing the practitioner,
pharmacist and patient or patient's agent, parent or guardian to cancel the
collaborative practice agreement at any time by written notice to all parties.
The pharmacist shall retain the original notice of cancellation for two (2)
years; and
(vi) The signatures of
the pharmacist and prescribing practitioner who are entering into the
collaborative practice agreement and the dates when signed.
(c) MTM shall occur only for a
particular patient pursuant to a specific written order from the prescribing
practitioner. The written order shall conform to the format established by the
Board and shall include the following as a minimum:
(i) Patient's name, gender, date of birth,
height and weight;
(ii)
Allergies;
(iii) Medical
diagnosis;
(iv) All current
medication(s), including current dosages (including any laboratory
test);
(v) Method of communicating
information between pharmacist and practitioner;
(vi) Frequency of practitioner
follow-up;
(vii) Date the order
will be renewed (specific order must be renewed annually); and
(viii) Signatures of the practitioner,
pharmacist and patient or the patient's agent, parent or guardian, and date
signed.
(d) A pharmacist
providing MTM for a patient shall obtain written consent from the patient or
the patient's agent, parent or guardian prior to providing this service. MTM
shall not be implemented for a particular patient, if the patient or patient's
agent, parent or guardian refuses to give written consent after being informed
of the responsibility for payment.
(e) At a minimum, the written collaborative
practice agreement shall be reviewed and renewed annually. If necessary, the
collaborative practice agreement may be revised. The Board must approve all
revisions, once signed by the pharmacist and the prescribing practitioner,
prior to implementation. The Board shall review and approve all collaborative
practice agreements, including revisions, prior to implementation. This shall
be accomplished as follows:
(i) The Board
shall appoint a Collaborative Practice Advisory Committee. The Committee shall
be composed of five (5) members. Composition shall be two (2) pharmacists
currently licensed by the Board and in active practice in Wyoming, one of whom
is a current member of the Board; two (2) physicians currently licensed by the
Wyoming State Board of Medicine and in active practice in Wyoming one of whom
is a current member of the Board of Medicine; and the Board of Pharmacy
Executive Director;
(ii) A
pharmacist who has developed a collaborative practice agreement shall forward
five (5) copies of the signed collaborative practice agreement to the Board.
The Executive Director shall convene the Committee to review pending
collaborative practice agreements. The Committee shall have authority to
recommend approval or rejection of the collaborative practice
agreement;
(iii) The recommendation
of the Committee shall be reported to the Board at their next regularly
scheduled meeting or as needed. The Board's decision will be delivered to the
pharmacist and prescribing practitioner within ten (10) days of the Board's
decision; and
(iv) The pharmacist
submitting a collaborative practice agreement or revisions to an approved
collaborative practice agreement to the Board shall not practice under the
collaborative practice agreement until notified of approval by the Executive
Director.
(f) A
pharmacist and prescribing practitioner entering into a collaborative practice
agreement must be currently licensed by their respective boards and authorized
to practice in this State.
(g)
Nothing in this section shall be interpreted to permit a pharmacist to accept
delegation of a physician's authority outside the limits included in W.S.
§
33-26-402 of the Medical Practice Act and the
Wyoming State Board of Medicine regulations.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.